MIRA Pharmaceuticals Announces Promising Results for Ketamir-2 Topical Formulation

MIRA Pharmaceuticals has completed in vitro release testing for its Ketamir-2 topical formulation aimed at pain-related conditions. The study showed consistent and dose-proportional release using a Franz diffusion cell model. Ketamir-2 stayed stable within a hydrophobic base, meeting FDA guidelines. This positions MIRA to address a broader pain market, presenting a significant commercial opportunity.

MIRA is advancing preclinical studies to evaluate the formulation in inflammatory and neuropathic pain models. The U.S. topical pain relief market, projected to exceed $11.5 billion by 2025, reflects a growing interest in non-opioid treatments.

The company is exploring FDA Fast Track designation for Ketamir-2, vital for chronic pain affecting millions in the U.S. MIRA also progresses with its oral formulation of Ketamir-2, complementing its multi-route approach.